Summit Therapeutics
Inc.(‘Summit,’ the ‘Company,’ or the ‘Group’)
Summit Therapeutics Appoints Dr. Mahkam
(“Maky”) Zanganeh as Chief Operating Officer
Cambridge, MA, November 23,
2020 – Summit Therapeutics Inc. (NASDAQ: SMMT) announces
that Dr. Mahkam “Maky” Zanganeh, DDS, MBA, has been appointed
as Chief Operating Officer, effective immediately. Dr.
Zanganeh is currently a member of the Company’s Board of Directors,
having been appointed on November 11, 2020.
“Maky’s strategic leadership and operational
expertise provide immeasurable value to Summit, as she joins us
during this critical time within our ongoing Phase 3 clinical
trials of our precision antibiotic candidate, ridinilazole, where
we seek to bring a superior treatment to patients with C. difficile
infection,” said Bob Duggan, Executive Chairman and Chief Executive
Officer of Summit. “Maky’s proven track record of translating
strategic objectives into results will help propel our Company as
we build a viable, long-lasting health care organization that
improves quality of life, increases potential duration of life, and
resolves medical health care needs.”
Dr. Zanganeh joins Summit from
Maky Zanganeh and Associates (“MZA”), which provides
consulting services to businesses in product development, research,
and transactions, where she
is the President and CEO. Prior to founding and
leading MZA, Dr. Zanganeh held multiple leadership positions
at Pharmacyclics, Inc., from 2008 to 2015, culminating in her
role as Chief Operating Officer, where she oversaw all clinical,
research, commercial, and business-related matters.
Dr. Zanganeh played a key role in the multimillion-dollar
collaboration and license deal for ibrutinib with Janssen Biotech,
Inc. in 2011, and the subsequent sale of Pharmacyclics to Abbvie
Inc. in 2015. She is currently a board member for
Pulse BioSciences, Inc., and RenovoRx, Inc. Dr. Zanganeh
received her DDS from the Louis Pasteur University (France) and her
MBA from Schiller International University (France).
“The opportunity that Summit has to change the
standard of care for infectious diseases, starting with
ridinilazole, and improve the long-term quality of life of patients
is pivotal to the antibiotics landscape,” stated Dr. Zanganeh.
“I look forward to expanding my role with a team of world
class scientists and business leaders in assisting with the
continuing build out of a powerful, sustainable business model to
develop and commercialize our novel antibiotics, as we improve
outcomes for patients and create healthcare savings in the
process.”
About Summit Therapeutics
Summit Therapeutics, empowered by its Discuva
Platform, the Company’s innovative antibiotic discovery engine,
supported by BARDA and Carb-X funding, intends to be the leader in
patient- and physician-friendly, paradigm-shifting antibiotic
innovation. Our new mechanism antibiotics are designed to become
the patient-friendly, new-era standard of care, by working in
harmony with the human microbiome to treat prospective patients
suffering from infectious disease, initially focusing on
Clostridioides difficile infections (“CDI”) which is estimated to
impact over 3 million patients worldwide annually.
Commercialization of ridinilazole for the treatment and the
reduction of recurrence of CDI is subject to regulatory approvals.
The overriding objective of Summit Therapeutics is to create value
for patients, hospital infectious disease caregivers,
community-based infectious disease healthcare providers, as well as
healthcare payors around the world. Currently, Summit’s lead
product candidate, ridinilazole, is engaged in two global Phase III
trials, Ri-CoDIFy 1 & 2, each enrolling 680 patients vs. the
standard of care (Vancomycin) for the treatment and reduction of
recurrence of C. difficile infections.
Summit’s vision and mission is to extend our
pipeline through the development of new mechanism, narrow spectrum,
microbiome-sparing antibiotics targeting C. difficile,
Gram-negative Enterobacteriaceae, such as Escherichia coli and
Klebsiella pneumoniae, and other bacterial infections with high
unmet medical need.
For more information, visit www.summittxinc.com
and follow us on Twitter @summitplc. For more information on the
Company’s Discuva Platform, visit
https://www.summittxinc.com/our-science/discuva-platform.
Contract Summit Investor
Relations:
Dave Gancarz
Vice President, Investor Relations &
Corporate Strategy
david.gancarz@summitplc.com
General Inquiries:
investors@summitplc.com
Summit Forward-looking
Statements
Any statements in this press release about the
Company’s future expectations, plans and prospects, including but
not limited to, statements about the clinical and preclinical
development of the Company’s product candidates, the therapeutic
potential of the Company’s product candidates, the potential
commercialization of the Company’s product candidates, the timing
of initiation, completion and availability of data from clinical
trials, the potential submission of applications for marketing
approvals, the impact of the COVID-19 pandemic on the Company’s
operations and clinical trials and other statements containing the
words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "would," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
uncertainties inherent in the initiation of future clinical trials,
availability and timing of data from ongoing and future clinical
trials and the results of such trials, global public health crises,
including the coronavirus COVID-19 outbreak, that may affect timing
and status of our clinical trials and operations, whether
preliminary results from a clinical trial will be predictive of the
final results of that trial or whether results of early clinical
trials or preclinical studies will be indicative of the results of
later clinical trials, expectations for regulatory approvals, laws
and regulations affecting government contracts and funding awards,
availability of funding sufficient for the Company’s foreseeable
and unforeseeable operating expenses and capital expenditure
requirements and other factors discussed in the "Risk Factors"
section of filings that the Company makes with the Securities and
Exchange Commission. Accordingly, readers should not place undue
reliance on forward-looking statements or information. In addition,
any forward-looking statements included in this press release
represent the Company’s views only as of the date of this release
and should not be relied upon as representing the Company’s views
as of any subsequent date. The Company specifically disclaims any
obligation to update any forward-looking statements included in
this press release.
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024